| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615744 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 33 Pages |
Abstract
The pegfilgrastim-rituximab combination was well tolerated, with favorable outcomes compared with historical controls. AÂ shorter time-to-peak oxidative burst was associated with higher CR rates and longer PFS. Our results support further evaluation of strategies that enhance the innate immune system to improve rituximab activity in B-NHL.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Pallawi Torka, Priyank Patel, Wei Tan, Gregory Wilding, Seema A. Bhat, Myron S. Czuczman, Kelvin P. Lee, George Deeb, Vishala Neppalli, Cory Mavis, Paul Wallace, Francisco J. Hernandez-Ilizaliturri,